Tag Archives | companion diagnostics

2018 J.P.Morgan Healthcare Conference #4 Notes from Panel: Key Trends in Diagnostics and Lifesciences

enter site Key Trends in Diagnostics and Lifesciences: Promise, Reality Reimbursement Panel Moderator: Ken Bahk, Three Lake Partners. Panelists- Nathan Ledeboer, Medical College of Wisconsin,Victoria Pratt, Indiana University School of Medicine, Nick Papadopolous, Johns Hopkins School of Medicine. Here are some takeaways from the session that covers novel tests, clinical diagnostic reimbursement and CPT codes(no slides were […]

Continue Reading 0

What’s Up With Diagnostics and Tools Stocks? Big Winners Are In Personalized Medicine- FMI, ILMN

http://oceanadesigns.net/wp-json/oembed/1.0/embed?url=http://oceanadesigns.net/envira/autumn-swirl/ Clinical Diagnostics and Tools: Big Winners Are In Genomics and Personalized Medicine Slower growth in routine clinical diagnostics, tools are favored. Hologic has a unique business model for women’s health and diagnostics. Gene sequencing is important for future clinical applications and biopharma R&D. We haven’t updated our Clinical Diagnostics and Tools Portfolio since the severe […]

Continue Reading 0

BIO International Convention 2017 Update #3: Genomics and Future of Personalized Medicine

http://sdsignshop.com/product/new-home-rider-6″t-x-18″w/?add_to_wishlist=2418 Genomics and the Future of Personalized Medicine and Diagnostics Description of Track The opening plenary of the Personalized Medicine & Diagnostics Track will feature J. Craig Venter, Founder, Chairman and Chief Executive Officer of the J. Craig Venter Institute, a not-for-profit, research organization with approximately 250 scientists and staff dedicated to human, microbial, plant, synthetic […]

Continue Reading 0

BIO International Convention 2017 Updates #2-BIG Data Drives Precision Medicine

 Big Data Provides Pathway to Precision Medicine Description of Track Speaker Atul Butte, MD,Ph.D. Director, UCSF Institute for Computational Health Sciences The remarkable ascent of Big Data for example from biomedical imaging, next generation sequencing and adjacent technologies that deliver a multiplicity of heterogeneous data has been a tremendous boon for basic biomedical research and […]

Continue Reading 0

Notes from J.P.Morgan Conference 2017: Sequencing (NGS) Moves to Toward Clinical Diagnostic Solutions

Outlook and Issues for Application of NGS for Clinical Diagnostics We heard a few presentations on NGS solutions and still think it is an important growth market for clinical diagnostics in oncology, rare diseases transplant medicine and NIPT. Gene sequencing (NGS) can lead to a better understanding of the molecular basis of disease and personalize diagnostics and […]

Continue Reading 0

Life Science Sector Review: Diagnostics and Tools Update

Life Science Sector: What’s Going On With Dx and Tools Stocks? We dropped coverage of Life Science diagnostics and tools stocks in January 2016 just after the severe market correction began. Of course the downdraft opened up great values in several stocks.We have reviewed selected stocks in the sector with the idea that more opportunities […]

Continue Reading 0

BIO Investor Forum 2016 #2:”Liquid Biopsy” Tests for Cancer…Update-1

CLIA Labs Offer Liquid Biopsy Tests for Cancer and Precision Medicine We attended presentations from two emerging companies developing molecular diagnostics platforms focused in cancer.Their mission is to develop cost-effective, non-invasive diagnostic assays and biomarkers directly from blood or urine eliminating  the need for tissue samples, the “liquid biopsy”.With DNA sequencing broadly available it is […]

Continue Reading 0

Illumina (ILMN) Misses Revenue Forecast Causing Collateral Damage to Biotechs

Update-1 Biotechs Sinking Again …IBB down 2.48%, ILMN down another 2% Related sequencing stocks: FMI down 1.75%, PACB flat at $8.40 Illumina (ILMN) Shares Crash on Revenue Miss Illumina (ILMN) shares crashed 25% to $139, after a warning on third quarter sales . The global leader in DNA sequencing systems warned that revenues missed forecast and would […]

Continue Reading 0

Deal of the Day: Cepheid (CPHD) Sells Out to Danaher (DHR) for $4B

M&A Deal of the Day: Cepheid (CPHD) up 50% Over Friday Close on Cash Buyout We have been spending too much time on biopharma. It is time to dust off our Dx and Tools portfolio, which is on hold, and find some value stocks for Q4 moves. We did an update in Q4 of 2015 […]

Continue Reading 0

Today’s Movers in Life Sciences-Gene Sequencing: ILMN,PACB

Illumina (ILMN) Up 3 % to $174 on Buyout Speculation in Gene Sequencing Illumina, Inc. (ILMN) was up as much as 12 points earlier today on a rumored buyout from Thermo Fisher Scientific Inc. (TMO).  Thermo bought another major player in sequencing Life Techologies for $13.6B making it the number two player in the major […]

Continue Reading 0